Fabry Disease Screening in Kidney Transplant Recipients: A Single-Center Retrospective Study
Öz
Background: Fabry disease (FD) is an X linked lysosomal storage disorder caused by deficient α galactosidase A (α GAL A) activity, leading to progressive multisystem involvement, including kidney disease. Evidence on FD screening in kidney transplant recipients is limited. We aimed to evaluate the results of FD screening tests requested due to clinical suspicion in kidney transplant recipients followed at a tertiary referral center.
Methods: This single center retrospective observational study included 59 kidney transplant recipients for whom FD screening was requested between January and February 2022. Dried blood spots (DBS) were used in both sexes. Female recipients underwent direct GLA next generation sequencing (NGS) from DBS without enzyme testing. Male recipients underwent fluorometric measurement of α GAL A activity from DBS; cases with low/borderline activity underwent confirmatory GLA NGS. Genetic analyses were performed at Düzen Laboratory in Ankara. Clinical and demographic data were extracted from electronic records.
Results: Mean age was 54.80±12.30 years and 27 recipients were female. Among 32 male recipients, α GAL A activity was ≤2.5 nmol/mL/h in three cases; confirmatory GLA NGS was negative in all. Two female recipients had heterozygous GLA variants [c.937G>T (p.Asp313Tyr, D313Y) and c.894T>C (p.Asn298=)] without overt FD phenotype in available records.
Conclusions: Enzymatic abnormalities and/or GLA variants may be identified in kidney transplant recipients even in small cohorts. Borderline enzyme activity results and variants of uncertain significance should be interpreted together with genetic confirmation and careful clinical correlation.
Anahtar Kelimeler
Fabry disease;, Kidney transplantation;, Alpha‑galactosidase A;, GLA gene;, Screening
Destekleyen Kurum
The authors received no financial support for the research, authorship, or publication of this article. There is no funding source.
Etik Beyan
This study was approved by the Clinical Research Ethics Committee of Ankara Bilkent City Hospital (Approval Date: 21.12.2025; Approval Number: TABED 1-25-1998). The study was conducted in accordance with the principles of the Declaration of Helsinki. Written informed consent was obtained from all participants. The study did not involve any animal subjects.
Teşekkür
None. No person other than the listed authors contributed to this study in a manner that would require acknowledgement.
Kaynakça
- Germain DP. Fabry disease. Orphanet J Rare Dis. 2010; 5:30.
- Ortiz A, Germain DP, Desnick RJ, Politei J, Mauer M, Burlina A, et al. Fabry disease revisited: management and treatment recommendations for adult patients. Mol Genet Metab. 2018;123(4):416-427.
- Schiffmann R, Hughes DA, Linthorst GE, Ortiz A, Svarstad E, Warnock DG, West ML, Wanner C; Conference Participants. Screening, diagnosis, and management of patients with Fabry disease: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. Kidney Int. 2017;91(2):284-293.
- Vardarli I, Rischpler C, Herrmann K, Weidemann F. Diagnosis and screening of patients with Fabry disease. Ther Clin Risk Manag. 2020; 16:551-558.
- Chamoles NA, Blanco M, Gaggioli D. Fabry disease: enzymatic diagnosis in dried blood spots on filter paper. Clin Chim Acta. 2001;308(1-2):195-196.
- Linares D, Luna B, Loayza E, Taboada G, Ramaswami U. Prevalence of Fabry disease in patients with chronic kidney disease: a systematic review and meta-analysis. Mol Genet Metab. 2023;140(4):107714.
- Veroux M, Monte IP, Rodolico MS, Corona D, Bella R, Basile A, et al. Screening for Fabry disease in kidney transplant recipients: experience of a multidisciplinary team. Biomedicines. 2020;8(10):396.
- Monda E, Diana G, Graziani F, Rubino M, Bakalakos A, Linhart A, et al. Impact of GLA variant classification on the estimated prevalence of Fabry disease: a systematic review and meta-analysis of screening studies. Circ Genom Precis Med. 2023;16(6):e004252.
- Yalın SF, Eren N, Sinangil A, et al. Fabry disease prevalence in renal replacement therapy in Turkey. Nephron. 2019;142(1):26-33.
- Erdogmus S, Kutlay S, Kumru G, Ors Sendogan D, Erturk S, Keven K, Ceylaner G, Sengul S. Fabry disease screening in patients with kidney transplant: a single-center study in Turkey. Exp Clin Transplant. 2020;18(4):444-449.